Treatment of acute ischemic stroke: Role of ischemic tolerance in intravenous and endovascular therapies

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 4, 2009, Pages 331-332

  Cornelius, Jan F ^a   Sandu, Nora ^b   Perez Pinson, Miguel A ^c   Schaller, Bernhard ^a  

^a University of Paris   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; GLUCOSE; NEUROPROTECTIVE AGENT; OXYGEN; FIBRINOLYTIC AGENT;

BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; EDITORIAL; HUMAN; INDUCED HYPOTHERMIA; NERVE CELL NECROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; REPERFUSION INJURY; STROKE PATIENT; ACUTE DISEASE; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; PATHOPHYSIOLOGY; STROKE;

ACUTE DISEASE; ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; STROKE;

EID: 67650290165     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.18     Document Type: Editorial

References (17)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1587 (1995).
2. Heiss WD, Grond M, Thiel A et al. Ischaemic brain tissue salvaged from infarction with alteplase. Lancet 349, 1599-1600 (1997).
3. Hacke W, Kaste M, Bluhmki E et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317-1329 (2008).
4. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic Therapy in Acute Ischemic Stroke Study investigators. Stroke 31, 811-816 (2000).
5. Segura T, Calleja S, Jordan J. Recommendations and treatment strategies for the management of acute ischemic stroke. Expert Opin. Pharmacother. 9, 1071-1085 (2008).
6. Schaller B, Graf R, Jacobs AH. Ischemic tolerance: a window to endogenous neuroprotection. Lancet 362, 1007-1008 (2003).
7. Schaller B. Trigeminocardiac reflex. A clinical phenomenon or a new physiological entity? J. Neurol. 251, 658-665 (2004).
8. Schaller B. Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance. Neurosci. Lett. 377, 206-211 (2005).
9. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363-389 (2008).
10. Chen SD, Lee JM, Yang DI, Nassief A, Hsu CY, Combination therapy for ischemic stroke: potential of neuroprotectants plus thrombolytics. Am. J. Cardiovasc. Drugs 2, 303-313 (2002).
11. Schaller B. The role of endothelin in stroke: experimental data and 867 underlying pathophysiology. Arch. Med. Sci. 2, 146-158 (2006).
12. Schaller B, Graf R. Hypothermia and stroke: the pathophysiological background. Pathophysiology 10, 7-35 (2003).
13. Tang XN, Liu L, Yenari MA. Combination therapy with hypothermia for treatment of cerebral ischemia. J. Neurotrauma DiOI: 10.1089/ neu.2008.0594 (2009).
14. Den Hertog HM, van der Worp HB, Tseng MC, Dippel DW. Cooling therapy for acute stroke. Cochrane Database Syst. Rev. 1, CD001247 (2009).
15. Haverich A, Scott WC, Jamieson SW. Twenty years of lung preservation - a review. J. Heart Transplant. 4, 234-240 (1985).
16. Wittwer T, Wahlers T, Fehrenbach A et al. Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung. J. Heart Lung Transplant. 18, 684-692 (1999).
17. Fischer S, Strueber M, Haverich A. Clinical cardiac and pulmonary transplantation: the Hannover experience. Clin. Transpl. 311-316 (2000).